0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum:  A Case Series and Literature Review FREE

Jennifer L. Hsiao, BS; Richard J. Antaya, MD; Timothy Berger, MD; Toby Maurer, MD; Kanade Shinkai, MD, PhD; Kieron S. Leslie, MB, BS, MRCP
[+] Author Affiliations

Author Affiliations: Department of Dermatology, University of California at San Francisco (Ms Hsiao and Drs Berger, Maurer, Shinkai, and Leslie); and Departments of Dermatology and Pediatrics, Yale University, New Haven, Connecticut (Dr Antaya).


Arch Dermatol. 2010;146(11):1265-1270. doi:10.1001/archdermatol.2010.328.
Text Size: A A A
Published online

Background  Hidradenitis suppurativa (HS) and pyoderma gangrenosum (PG) are both rare inflammatory skin conditions that are associated with systemic inflammatory diseases. We performed a retrospective medical chart review of patients with an overlap of HS and PG.

Observations  We identified 11 cases of PG lesions presenting in patients with HS. Ten of the patients were women, and 9 were obese. All the patients developed HS lesions first, a median of 2.5 years (range, 0-15 years) preceding the appearance of PG lesions. All patients required multiple therapeutic agents because their diseases were often poorly responsive to standard therapies. Two patients received tumor necrosis factor inhibitors; 1 responded to treatment. One patient was treated with anakinra (interleukin-1 receptor antagonist) and had a 75% improvement of her lesions.

Conclusions  We have identified a group of patients who have an overlap of PG and HS. Pyoderma gangrenosum can appear at any point after the development of HS and often has a severe, refractory course. We propose that PG and HS may represent variant manifestations of cytokine dysregulation by the innate immune system with common etiology. New therapeutic agents are eagerly sought, and further investigation with regard to interleukin 1 blockade is warranted.

Figures in this Article

Pyoderma gangrenosum (PG) is a rare inflammatory skin condition with lesions most commonly appearing on the lower extremities but which may occur anywhere else on the body.1 The classic ulcerative PG lesion presents as a painful nodule or pustule that breaks down and evolves into an enlarging ulcer with a raised, undermined border.2 Approximately 50% of patients with PG have associated systemic diseases, including inflammatory bowel disease (IBD), myeloproliferative disorders, and inflammatory arthritis.3,4 Biopsy specimens from the edge of the ulcers typically show neutrophilic inflammation, and lesions further evolve to demonstrate a suppurative granulomatous dermatitis.2

Hidradenitis suppurativa (HS) typically presents in the axillae, perineum, and inframammary sites and is characterized by the presence of multiple abscesses, fibrosis, and sinus tracts.5 It is associated with acne, Crohn disease, dissecting cellulitis of the scalp, obesity, pilonidal disease, and smoking, and, like PG, HS has nonspecific histologic findings.5,6

The appearance of HS and PG lesions in the same patient has been rarely reported. We defined patients to include in this series as those having clinical diagnoses of HS and either PG lesions in HS sites or PG lesions in other body sites. Patients meeting inclusion criteria were identified by clinicians at University of California, San Francisco, and Yale University, New Haven, Connecticut. This was a retrospective medical chart review and literature review.

We identified 11 patients who met our criteria for having an overlapping presentation of HS and PG. Patients were included if they presented with morphologic characteristics consistent with HS (eg, with multiple aseptic abscesses, sinus tracts, and scarring in intertriginous sites) and in addition had ulcerations and histologic findings (where available) consistent with PG either in the same anatomical location as their HS lesions or in a distant location, such as the legs. We identified an ulcer as PG based on the clinical presentation of a rapidly expanding painful ulcer with undermined edges. The characteristics of these patients are summarized in the Table. The median age of HS onset was 20.5 years (range, 14-32 years), and the median age of PG onset was 23 years (range, 16 to ≥32 years). Hidradenitis suppurativa lesions were mostly found in the typical intertriginous sites, with 1 patient (case 9) having all of her skin folds affected, including folds on her back and posterior neck (Figure 1). With the exception of 1 patient (case 4), all of the patients were women. Nine of the 10 women in the case series were obese. Other comorbidities included type 2 diabetes mellitus (5 patients), coronary artery disease (1 patient), acanthosis nigricans (4), acne (3), hypertension (3), anemia (5), asthma (2), colitis (2), gastritis (1), arthritis (1), depression (5), and anxiety (1). Three patients had a history of pilonidal cyst/sinus (cases 1, 3, and 8). Two distinct groups were identified: patients with PG in sites where the patient had HS lesions (n = 6 patients) and those with PG in sites distinct from HS lesions (n = 5 patients).

Place holder to copy figure label and caption
Figure 1

Case 9. A 14-year-old girl with hidradenitis suppurativa, with chronic painful, draining linear ulcerations in her left axilla and abdominal fold (A), and a pyoderma gangrenosum lesion on her leg that partially responded to treatment with anakinra (B). No disease-associated mutation was identified in the Pyoderma gangrenosum, Acne, and Pyogenic Arthritis syndrome gene.

Graphic Jump Location
Table Graphic Jump LocationTable. Summary of Clinical Presentations in the Current Series and in a Literature Review of Patients With Pyoderma Gangrenosum (PG) and Hidradenitis Suppurativa (HS) (continued)
CASES WITH PG IN HS CONCOMITANT SITES

Slightly more than half of patients (cases 1-6) had PG lesions develop in the same sites affected by their HS disease (Figure 2). For these patients, PG lesions developed a median of 2 years (range, 0-7 years) after HS had been present and affected the breasts, groin, axillae, and buttocks. One patient (case 2) had HS and PG lesions that presented around the same time, so the onset of PG lesions was counted as occurring 0 years after HS onset; in every other case HS preceded PG lesions by at least 1 year. The PG lesions of 1 patient resolved after a month; to date, 4 other patients still have active lesions.

Place holder to copy figure label and caption
Figure 2

Case 1. A 23-year-old woman with 2-year history of hidradenitis suppurativa who presented with a right inframammary pyoderma gangrenosum ulcer.

Graphic Jump Location
CASES WITH PG IN HS DISTINCT SITES

Four of these patients (cases 8-11) had classic PG lesions on their legs, and 1 patient (case 7) had a PG lesion on her breast. One patient (case 9) developed ulcerations in a linear pattern in areas of old HS scarring, and it was unclear if these ulcerations were predominantly PG or if they were chronic HS ulcerations. Patient 9 also had classic PG lesions on her legs (Figure 1). Of these 5 patients, PG developed a median of 3 years (range, 2-15 years) after HS onset. One patient had resolution of her PG lesions after 15 months. Two other patients still have active lesions to date; 1 patient has had PG for over 10 months, and another has had PG lesions for over 18 years.

HISTOPATHOLOGIC CHARACTERISTICS

Seven patients had biopsy specimens taken of their PG lesions. All biopsy specimens demonstrated a mixed inflammatory infiltrate, including neutrophils. Findings from special stains and tissue cultures when performed were negative for infection. The histologic findings were consistent with the diagnosis of PG.

LABORATORY MARKERS OF INFLAMMATION

Four patients had leukocytosis, and 3 of them had an elevated absolute neutrophil count. The C-reactive protein was measured in 4 patients; 2 had elevated levels: 8.1 mg/L and 15.9 mg/L (reference range, 0-6.3 mg/L). The erythrocyte sedimentation rate (ESR) was increased in 3 patients of the 4 in whom it was measured: 62 mm/h, 63 mm/h, and 130 mm/h (reference range, 0-15 mm/h).

TREATMENTS

The patients with PG in HS concomitant sites were as follows: 1 patient (case 5) had lesions that resolved 1 month after treatment with doxycycline and intralesional triamcinolone acetonide. To date, 4 patients still have active lesions. Two patients were treated with tumor necrosis factor (TNF) inhibitors; 1 patient (case 2) had a partial response while receiving treatment with etanercept, was switched to infliximab, but showed no further improvement, and the other (case 4) failed treatment with infliximab and then with adalimumab. The lesions of the latter patient (case 4) showed minimal improvement during treatment with anakinra, an interleukin 1 (IL-1) antagonist, after 1 month and substantial improvement when treated with cyclosporine. All of these patients were treated with intralesional triamcinolone at some point during their course, with at least partial success in each case.

The patients with PG in HS distinct sites were as follows: the PG lesions in 1 patient (case 10) responded to tacrolimus ointment and minocycline after failing treatment with thalidomide and prednisone, 20 to 80 mg/d, and another patient (case 8) had a partial response to dapsone cream and prednisone, 40 mg/d, thus far. One patient (case 9) had a very refractory course of disease, failing treatment with minocycline, cyclosporine, topical tacrolimus, and topical and systemic steroids. She had a 75% improvement in size and depth of her PG ulcers after 3 weeks of treatment with anakinra, 100 mg/d subcutaneously (Figure 1). Six weeks later when she was not receiving therapy, her ulcers enlarged again, and they showed a partial response to rifampin and clindamycin hydrochloride. Follow-up information on response to treatments was not available for 3 patients (cases 6, 7, and 11).

We found 20 cases of concomitant PG and HS from a search of the English-language, peer-reviewed literature. The characteristics of these patients are summarized in the Table. Seven of the patients were women, and 8 were men. The median age at HS onset was 24 years (range, 17-40 years), and the median age at PG onset was 43 years (range, 32-57 years). Pyoderma gangrenosum developed a median of 19 years after HS onset (range, 5 months to 30 years). The HS lesions were mostly in the axillae, groin, and buttocks. One patient was described as having PG and HS in the same site,7 and 12 had PG lesions in sites distinct from their HS affected sites, such as on the lower extremities (10 cases). Comorbidities included acne (7 cases), arthritis (3 cases); Synovitis, Acne,Pustulosis, Hyperostosis, and Osteitis (SAPHO) syndrome (3 cases); iron-deficiency anemia (1); lupus (1); glomerulonephritis (1); psoriasis (1); Crohn disease (1); and Behcet disease (1). The PG lesions lasted a median of 1 year (range, 1 week to 6 years).

Our case series is different from prior case reports in that in our patients, PG developed in a much shorter time period (median period, 3 years) after HS had been present compared with prior case reports (median period, 2 decades). We also saw a predominance of women, which may just reflect that HS is a more common disease in women.15 To our knowledge, the epidemiology of PG has not been reported in the literature, so it is unclear if there is sex disequilibrium. In addition, we were surprised by the low prevalence of IBD in both our patients and prior cases given its association with HS and with PG; 2 of our 11 patients (18%) had nonspecific colitis, and only 1 patient in the 20 prior cases (5%) was reported to have any bowel disease (Crohn disease). Finally, most of our patients were obese, a characteristic which had not been commented on in the previous case reports, and which may just be reflective of typical patients with HS.16

The pathogenesis for both HS and PG is incompletely understood. Hypothesized etiologic factors for HS include follicular plugging, leading to rupture of the pilosebaceous unit and a resulting inflammatory response, abnormal apocrine gland secretion, and endocrinologic factors, such as hyperandrogenism; bacteria are thought to likely play a secondary role in exacerbating the disease.5 The pathogenesis of PG is also unknown, although neutrophil defects in chemotaxis or hyperreactivity have been suggested as possible etiologic factors.2 Both diseases are characterized by an intense inflammatory response that is mediated by neutrophils, and both diseases are commonly seen with other inflammatory processes such as IBD. Crohn disease is thought to be a member of the class of autoinflammatory diseases, or diseases characterized by systemic inflammation from dysregulated innate immune signaling pathways in the absence of autoantibodies or antigen-specific T cells.17 In addition, PG and HS are features of the Pyoderma gangrenosum, Acne, and Pyogenic Arthritis (PAPA) syndrome, a recognized autoinflammatory disease resulting from overexpression of IL-1β.18,19 Other autoinflammatory conditions, such as Behcet disease, are associated with PG2 and SAPHO is associated with HS.5

Our patients demonstrated evidence of systemic inflammation with elevated acute phase reactants and multiple comorbidities also associated with proinflammatory phenotypes, such as obesity, type 2 diabetes mellitus, and coronary artery disease.20,21 We suggest that PG and HS may be in part due to dysregulation of the innate immune system, and that these diseases may be considered to be within the spectrum of the cutaneous disorders seen with the recently described autoinflammatory syndromes. Our hypothesis could tie into some of the current ideas regarding the etiologies of HS and PG. For example, perhaps in patients with HS, the original trigger was follicular plugging causing rupture of the pilosebaceous unit; however, it is the exaggerated and uncontrolled inflammatory response of these individuals to this stimuli that causes HS lesions to develop. In patients with PG, neutrophil dysfunction could be a part of the dysregulated innate immune system of these individuals, who have also been found to have high levels of the inflammatory cytokine IL-8 in their skin ulcers.22

Tumor necrosis factor inhibitors have been found to be effective in treating both PG23,24 or HS2527 with or without underlying inflammatory bowel disease. Pyoderma gangrenosum lesions have been reported to improve in a patient with PAPA syndrome after treatment with anakinra,28 and 1 of our patients (case 9), who did not have a known PAPA (CD2BP1) gene mutation, had a 75% improvement in her refractory PG lesions after 3 weeks of treatment with anakinra, suggesting that IL-1 may also be involved in the pathogenesis of PG not associated with PAPA syndrome.

The consistent temporal relationship of PG occurring after HS in all reported cases thus far may suggest that PG may be a late-onset cutaneous manifestation of the same underlying inflammatory process that triggered the preceding HS. This inflammatory process is most commonly local, with coexistent PG and HS lesions. These overlap cases are not frequently reported. Distant PG lesions may occur in the patient with HS in the setting of systemic inflammation from the HS, analogous to PG occurring on the skin in a patient with IBD of the gut. It is conceivable that in overlap cases, HS with chronic ulcerations might resemble PG, and because PG and HS cannot be distinguished by histologic examination given that it is rare to see differentiating features on a biopsy specimen, such as sinus tracts in HS, this confers diagnostic uncertainty. We identified an ulcer as PG based on presentation of a rapidly expanding painful ulcer with dusky undermined borders, which clinically behaved more like PG than HS, a disease characterized by abscesses, fibrosis, and sinus tracts.

Individually, both HS and PG are frequently conditions that are difficult to effectively treat. Our experience and that of others treating patients with concomitant HS and PG has similarly been challenging. Systemic corticosteroids are still first-line treatment for PG, although they are not frequently used in HS owing to the chronic nature of HS and the adverse effect profile of long-term use of these agents. Corticosteroids have profound anti-inflammatory properties and likely exert their effects on multiple cellular pathways.29 Traditional antineutrophilic agents, such as dapsone and colchicine, have largely been ineffective treatments for HS and PG. Although 1 patient with concomitant HS, PG, and Behcet disease had PG lesions that initially resolved with colchicine treatment, 2 weeks later his PG relapsed, and treatment with prednisone, 60 mg/d, resulted in gradual improvement.11 Cyclosporine resulted in remissions in some patients, perhaps owing to its antineutrophilic properties.30 Antibiotics, particularly the tetracycline class, have been helpful in a minority of cases as adjunctive therapy and may reflect their anti-inflammatory effects with regard to the innate immune system.31 Anti-TNF therapies and now anti–IL-1 therapy are promising modalities, which are likely to be increasingly used in the future.

Last, we draw attention to the 7 patients in our case series with PG lesions in an HS distribution because of the possibly severe consequences of misdiagnosis. In 1 study of 44 patients with PG, lesions were enlarged in 8 patients by unsuccessful local surgical treatments before they were correctly diagnosed as PG.14 Given the lack of specific serologic or histopathologic studies to unequivocally distinguish between PG and HS in patients who have an overlap of the 2 diseases, we recommend medical treatment of these PG lesions if possible because surgical excision may worsen the patient's condition.

In summary, we describe 11 patients presenting with HS and concomitant PG lesions. We found that PG can occur in the same sites affected by HS or in distinct sites. Pyoderma gangrenosum in these patients is often refractory to the standard anti-inflammatory and antibiotic therapies, and TNF or IL-1 blockade may be helpful. We believe that there is a link between PG and HS and note that both share features with the class of autoinflammatory diseases. A better understanding of the underlying pathogenesis of PG and HS is needed to optimize treatment for these patients. This might include examining tissue and serum TNF and IL-1 levels and conducting further clinical trials with cytokine-blocking therapies.

Correspondence: Kieron S. Leslie, MB, BS, MRCP, Department of Dermatology, University of California, San Francisco, 1001 Potrero Ave, San Francisco General Hospital, Bldg 90, Ward 92, San Francisco, CA 94110 (lesliek@derm.ucsf.edu).

Accepted for Publication: April 16, 2010.

Author Contributions:Study concept and design: Hsiao, Shinkai, and Leslie. Acquisition of data: Hsiao, Antaya, Shinkai, and Leslie. Analysis and interpretation of data: Hsiao, Antaya, Berger, Maurer, Shinkai, and Leslie. Drafting of the manuscript: Hsiao, Antaya, and Leslie. Critical revision of the manuscript for important intellectual content: Hsiao, Antaya, Berger, Maurer, Shinkai, and Leslie. Statistical analysis: Hsiao. Administrative, technical, and material support: Shinkai. Study supervision: Antaya, Berger, Maurer, Shinkai, and Leslie.

Financial Disclosure: None reported.

Additional Contributions: Federico Inting provided assistance with data collection.

Powell  FCSchroeter  ALSu  WPPerry  HO Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985;55 (217) 173- 186
PubMed
Ruocco  ESangiuliano  SGravina  AGMiranda  ANicoletti  G Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;23 (9) 1008- 1017
PubMed
Powell  FCSu  WPPerry  HO Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34 (3) 395- 409
PubMed
Callen  JPJackson  JM Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007;33 (4) 787- 802, vi
PubMed
Alikhan  ALynch  PJEisen  DB Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009;60 (4) 539- 561
PubMed
Jemec  GBHansen  U Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996;34 (6) 994- 999
PubMed
Ah-Weng  ALangtry  JAVelangi  SEvans  CDDouglas  WS Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005;30 (6) 669- 671
PubMed
Moschella  SL Is there a role for infliximab in the current therapy of hidradenitis suppurativa? a report of three treated cases. Int J Dermatol 2007;46 (12) 1287- 1291
PubMed
Buckley  DARogers  S Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med 1995;88 (5) 289P- 290P
PubMed
Shenefelt  PD Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis 1996;57 (5) 315- 319
PubMed
Raynor  AAskari  AD Behçet's disease and treatment with colchicine. J Am Acad Dermatol 1980;2 (5) 396- 400
PubMed
Steinhoff  JPCilursu  AFalasca  GFGuzman  LReginato  AJ A study of musculoskeletal manifestations in 12 patients with SAPHO syndrome. J Clin Rheumatol 2002;8 (1) 13- 22
PubMed
Rosner  IARichter  DEHuettner  TLKuffner  GHWisnieski  JJBurg  CG Spondyloarthropathy associated with hidradenitis suppurative and acne conglobata. Ann Intern Med 1982;97 (4) 520- 525
PubMed
von den Driesch  P Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997;137 (6) 1000- 1005
PubMed
Jemec  GBHeidenheim  MNielsen  NH The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35 (2, pt 1) 191- 194
PubMed
Revuz  JECanoui-Poitrine  FWolkenstein  P  et al.  Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008;59 (4) 596- 601
PubMed
Galeazzi  MGasbarrini  GGhirardello  A  et al.  Autoinflammatory syndromes. Clin Exp Rheumatol 2006;24 (1) ((suppl 40)) S79- S85
PubMed
Shoham  NGCentola  MMansfield  E  et al.  Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003;100 (23) 13501- 13506
PubMed
Rosi  YLLowe  LKang  S Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005;16 (1) 58- 61
PubMed
Dandona  PAljada  ABandyopadhyay  A Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25 (1) 4- 7
PubMed
Ross  R Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340 (2) 115- 126
PubMed
Oka  MBerking  CNesbit  M  et al.  Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 2000;80 (4) 595- 604
PubMed
Regueiro  MValentine  JPlevy  SFleisher  MRLichtenstein  GR Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98 (8) 1821- 1826
PubMed
Brooklyn  TNDunnill  MGShetty  A  et al.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006;55 (4) 505- 509
PubMed
Martínez  FNos  PBenlloch  SPonce  J Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001;7 (4) 323- 326
PubMed
Blanco  RMartínez-Taboada  VMVilla  I  et al.  Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009;145 (5) 580- 584
PubMed
Sullivan  TPWelsh  EKerdel  FABurdick  AEKirsner  RS Infliximab for hidradenitis suppurativa. Br J Dermatol 2003;149 (5) 1046- 1049
PubMed
Brenner  MRuzicka  TPlewig  GThomas  PHerzer  P Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009;161 (5) 1199- 1201
PubMed
Barnes  PJ Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005;25 (3) 451- 468
PubMed
Kountouras  JZavos  CChatzopoulos  D Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med 2004;8 (3) 317- 328
PubMed
Webster  GDel Rosso  JQ Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007;25 (2) 133- 135, v
PubMed

Figures

Place holder to copy figure label and caption
Figure 1

Case 9. A 14-year-old girl with hidradenitis suppurativa, with chronic painful, draining linear ulcerations in her left axilla and abdominal fold (A), and a pyoderma gangrenosum lesion on her leg that partially responded to treatment with anakinra (B). No disease-associated mutation was identified in the Pyoderma gangrenosum, Acne, and Pyogenic Arthritis syndrome gene.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2

Case 1. A 23-year-old woman with 2-year history of hidradenitis suppurativa who presented with a right inframammary pyoderma gangrenosum ulcer.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable. Summary of Clinical Presentations in the Current Series and in a Literature Review of Patients With Pyoderma Gangrenosum (PG) and Hidradenitis Suppurativa (HS) (continued)

References

Powell  FCSchroeter  ALSu  WPPerry  HO Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985;55 (217) 173- 186
PubMed
Ruocco  ESangiuliano  SGravina  AGMiranda  ANicoletti  G Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;23 (9) 1008- 1017
PubMed
Powell  FCSu  WPPerry  HO Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34 (3) 395- 409
PubMed
Callen  JPJackson  JM Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007;33 (4) 787- 802, vi
PubMed
Alikhan  ALynch  PJEisen  DB Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009;60 (4) 539- 561
PubMed
Jemec  GBHansen  U Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996;34 (6) 994- 999
PubMed
Ah-Weng  ALangtry  JAVelangi  SEvans  CDDouglas  WS Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005;30 (6) 669- 671
PubMed
Moschella  SL Is there a role for infliximab in the current therapy of hidradenitis suppurativa? a report of three treated cases. Int J Dermatol 2007;46 (12) 1287- 1291
PubMed
Buckley  DARogers  S Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med 1995;88 (5) 289P- 290P
PubMed
Shenefelt  PD Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis 1996;57 (5) 315- 319
PubMed
Raynor  AAskari  AD Behçet's disease and treatment with colchicine. J Am Acad Dermatol 1980;2 (5) 396- 400
PubMed
Steinhoff  JPCilursu  AFalasca  GFGuzman  LReginato  AJ A study of musculoskeletal manifestations in 12 patients with SAPHO syndrome. J Clin Rheumatol 2002;8 (1) 13- 22
PubMed
Rosner  IARichter  DEHuettner  TLKuffner  GHWisnieski  JJBurg  CG Spondyloarthropathy associated with hidradenitis suppurative and acne conglobata. Ann Intern Med 1982;97 (4) 520- 525
PubMed
von den Driesch  P Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997;137 (6) 1000- 1005
PubMed
Jemec  GBHeidenheim  MNielsen  NH The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35 (2, pt 1) 191- 194
PubMed
Revuz  JECanoui-Poitrine  FWolkenstein  P  et al.  Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008;59 (4) 596- 601
PubMed
Galeazzi  MGasbarrini  GGhirardello  A  et al.  Autoinflammatory syndromes. Clin Exp Rheumatol 2006;24 (1) ((suppl 40)) S79- S85
PubMed
Shoham  NGCentola  MMansfield  E  et al.  Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003;100 (23) 13501- 13506
PubMed
Rosi  YLLowe  LKang  S Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005;16 (1) 58- 61
PubMed
Dandona  PAljada  ABandyopadhyay  A Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25 (1) 4- 7
PubMed
Ross  R Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340 (2) 115- 126
PubMed
Oka  MBerking  CNesbit  M  et al.  Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 2000;80 (4) 595- 604
PubMed
Regueiro  MValentine  JPlevy  SFleisher  MRLichtenstein  GR Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98 (8) 1821- 1826
PubMed
Brooklyn  TNDunnill  MGShetty  A  et al.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006;55 (4) 505- 509
PubMed
Martínez  FNos  PBenlloch  SPonce  J Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001;7 (4) 323- 326
PubMed
Blanco  RMartínez-Taboada  VMVilla  I  et al.  Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009;145 (5) 580- 584
PubMed
Sullivan  TPWelsh  EKerdel  FABurdick  AEKirsner  RS Infliximab for hidradenitis suppurativa. Br J Dermatol 2003;149 (5) 1046- 1049
PubMed
Brenner  MRuzicka  TPlewig  GThomas  PHerzer  P Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009;161 (5) 1199- 1201
PubMed
Barnes  PJ Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005;25 (3) 451- 468
PubMed
Kountouras  JZavos  CChatzopoulos  D Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med 2004;8 (3) 317- 328
PubMed
Webster  GDel Rosso  JQ Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007;25 (2) 133- 135, v
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Nonspecific genital ulcers. Clin Dermatol 2014 Mar-Apr;32(2):259-74.